

AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing Of The Claims:

1. (Currently Amended) An isolated antibody comprising a variable heavy (VH) domain having a complementarity determining region (CDR) 1 having the amino acid sequence of SEQ ID NO:10, a VH CDR2 having the amino acid sequence of SEQ ID NO:18, a VH CDR3 having the amino acid sequence of SEQ ID NO:19, and framework regions having the amino acid sequence of the VH domain framework regions depicted in Figure 2B (SEQ ID NO:206) having the amino acid sequence of SEQ ID NO:48, wherein said antibody immunospecifically binds to a respiratory syncytial virus (RSV) F protein.
2. (Canceled)
3. (Currently Amended) An isolated antibody comprising a variable light (VL) domain having a CDR1 having the amino acid sequence of SEQ ID NO:21, a VL CDR2 having the amino acid sequence of SEQ ID NO:22, a VL CDR3 having the amino acid sequence of SEQ ID NO:6, and framework regions having the amino acid sequence of the VL domain framework regions depicted in Figure 2A (SEQ ID NO:205) ~~having the amino acid sequence of SEQ ID NO:20~~, wherein said antibody immunospecifically binds to a RSV F protein.
4. (Canceled)
5. (Currently Amended) The antibody of claim 3 further comprising a VH domain having a CDR1 having the amino acid sequence of SEQ ID NO:10, a VH CDR2 having the amino acid sequence of SEQ ID NO:18, a VH CDR3 having the amino acid sequence of SEQ ID NO:19, and framework regions having the amino acid sequence of the VH domain framework regions depicted in Figure 2B (SEQ ID NO:206) ~~having the amino acid sequence of SEQ ID NO:48~~.
- 6.-178. (Canceled)

179. (Currently Amended) An isolated antibody comprising a ~~complementarity determining region (CDR)~~ CDR having the amino acid sequence of a ~~VH CDR of the antibody A4B4~~ SEQ ID NO:10, SEQ ID NO:18 or SEQ ID NO:19, wherein said antibody immunospecifically binds to a RSV F protein.
180. (Previously Presented) An isolated antibody comprising a VH CDR1 having the amino acid sequence of SEQ ID NO:10, wherein said antibody immunospecifically binds to a RSV F protein.
181. (Previously Presented) An isolated antibody comprising a VH CDR2 having the amino acid sequence of SEQ ID NO:18, wherein said antibody immunospecifically binds to a RSV F protein.
182. (Previously Presented) An isolated antibody comprising a VH CDR3 having the amino acid sequence of SEQ ID NO:19, wherein said antibody immunospecifically binds to a RSV F protein.
183. (Previously Presented) An isolated antibody comprising a VL CDR1 having the amino acid sequence of SEQ ID NO:21, wherein said antibody immunospecifically binds to a RSV F protein.
184. (Previously Presented) An isolated antibody comprising a VL CDR2 having the amino acid sequence of SEQ ID NO:22, wherein said antibody immunospecifically binds to a RSV F protein.
185. (Canceled)
186. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:18.
187. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.
188. (Canceled)
189. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.

- 190.-191. (Canceled)
192. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
193. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
194. (Canceled)
195. (Previously Presented) The antibody of claim 184, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
- 196.-200. (Canceled)
201. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
- 202.-203. (Canceled)
204. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.
205. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
206. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
207. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.
208. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.

- 209. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
- 210. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.
- 211. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
- 212. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
- 213.-221. (Canceled)
- 222. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.
- 223. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
- 224. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
- 225. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.
- 226. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
- 227. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.

228.-230. (Canceled)

231. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.

232. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.

233. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.

234-240. (Canceled)

241. (Previously Presented) The antibody of claim 222, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.

242. (Previously Presented) The antibody of claim 223, wherein antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.

243. (Canceled).

244. (Previously Presented) The antibody of claim 225, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.

245. (Previously Presented) The antibody of claim 226, wherein antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.

246-249. (Canceled).

250. (Previously Presented) The antibody of claim 231, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.

251-279. (Canceled)

280. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a monoclonal antibody.

281. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a human antibody.
282. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a humanized antibody.
283. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a chimeric antibody, single chain Fv, single chain antibody, F(ab')₂ fragment, or Fab fragment.
284. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is conjugated to a therapeutic or drug moiety.
285. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is conjugated to a detectable substance.
286. (Previously Presented) A composition comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184 and a pharmaceutically acceptable carrier or excipient.
287. (Previously Presented) A kit comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, in one or more containers, and instructions for use.
288. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:10.
289. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:10.
290. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:10.
291. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:10.
292. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:18.

- 293. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:18.
- 294. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:18.
- 295. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:18.
- 296. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.
- 297. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.
- 298. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.
- 299. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.
- 300.-302. (Canceled)
- 303. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21 and a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
- 304. (Canceled)
- 305. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21, a VL CDR2 having the amino acid sequence of SEQ ID NO:22, and a VL CDR3 having the amino acid sequence of SEQ ID NO:6.

306. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21 and a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
307. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21, a VL CDR2 having the amino acid sequence of SEQ ID NO:22, and a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
308. (Currently Amended) An isolated antibody comprising a CDR having the amino acid sequence of ~~a VL CDR1 or a VL CDR2 of the antibody P12F2~~ SEQ ID NO:21 or SEQ ID NO:22, wherein said antibody immunospecifically binds to a RSV F protein.
309. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO: 19.
310. (Previously Presented) The antibody of claim 309, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO: 21.
311. (Previously Presented) The antibody of claim 309, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
312. (Previously Presented) The antibody of claim 309, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
313. (Previously Presented) The antibody of claim 310, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
314. (Previously Presented) The antibody of claim 310, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
315. (Previously Presented) The antibody of claim 311, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.

- 316. (Previously Presented) The antibody of claim 313, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
- 317. (Previously Presented) The antibody of claim 222, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
- 318. (Previously Presented) The antibody of claim 241, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
- 319. (Previously Presented) The antibody of claim 232, wherein the antibody comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
- 320. (Previously Presented) The composition of claim 286 formulated for pulmonary, intranasal or parenteral administration.
- 321. (Previously Presented) The composition of claim 286 which is a sustained release formulation.
- 322. (Previously Presented) A lyophilized formulation comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183 or 184.
- 323. (Previously Presented) A liquid formulation comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183 or 184.
- 324. (Previously Presented) A composition comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183 or 184.